Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

UNIVERSITÀ DEGLI STUDI DI MILANO

DECRETO DEL DIRETTORE GENERALE - N. 3975 del 07/10/2026 - Allegato Utente 1 (A01)

AGREEMENT FOR THE CO-FUNDING OF A SCHOLARSHIP FOR THE PHD PROGRAMME IN EXPERIMENTAL MEDICINE – 42nd CYCLE.

The University of Milan (fiscal code 80012650158), with registered office at Via Festa del Perdono 7, represented by Rector *pro tempore* Prof. Marina Brambilla, born in Milan on 2 June 1973, authorised to enter into this agreement by the Board of Directors – hereinafter "the University" –

AND

IGI Therapeutics S.A., with registered office in Neuchâtel (Switzerland), at Rue du Puits-Godet 8, (address) represented by Dean Thomas, born in Wythenshawe (United Kingdom) on April 22 1975, acting as General Counsel, duly authorized to execute on behalf of IGI Therapeutics S.A. – hereinafter "the Company " –

AND

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (C.F. 04724150968 / P.IVA 04724150968), with registered office in Milano, via FrancescoSforza 28, represented by Prof. Fabio Blandini, born in Messina on May 2nd 1962, acting as Scientific Director, appointed by the Legal Representative of the Organization, vested with the necessary powers pursuant to Board Resolution No. 10 of March 27, 2024 – hereinafter "Organization"

WHEREAS

- the University has established a PhD programme in Experimental Medicine;
- the Company, in a note dated April 24 2026 and received by the University on May 11 2026, has declared its intention to co-fund a scholarship for the PhD

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

programme, to be awarded to the highest-ranking applicant;

- the Organization, in a note dated May 4 2026 and received by the University on May 11 2026, has declared its intention to co-fund a scholarship for the PhD programme, to be awarded to the highest-ranking applicant;
- the Company and the Organization are interested in the implementation of the research project "*Evaluation of bone marrow niche for myeloma progression*" relating to the aforesaid PhD programme;

THE PARTIES HERETO AGREE AS FOLLOWS

Art. 1

The University undertakes to offer the scholarship co-funded by the Company and the Organization, together with those funded by the University, within the public competition for admission to the PhD programme in Experimental Medicine and to invite applications for said scholarship in the same competition notice, in compliance with current regulations.

The University will disburse the scholarship to the highest-ranking applicant meeting the requirements, in accordance with the deadlines and procedures provided for by current regulations.

Art. 2

The Company and the Organization undertake to pay the University the sum – arranged as it follows – that comprises for each programme year:

a) the scholarship, amounting to €18,400.00 as determined by the Board of Directors at the meeting of 24 February 2026;

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

b) INPS contributions under the separate management scheme, as envisaged by art. 2 of Ministerial Decree dated 11 September 1998, at the percentage rate currently applicable;

c) a contribution to the running costs of the PhD programme, in the amount of €1,550.00, as set by the University's Board of Directors;

d) a sum corresponding to no less than 10% of the amount of the scholarship, to be paid to each PhD student in addition to the scholarship, for research activity carried out in Italy and abroad;

IGI Therapeutics S.A. undertakes to pay the University a total of **€75,000.00**. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico undertakes to pay the University the remaining total of **€3,258.00**, together with:

e) the sum corresponding to no less than 50% of the amount of the scholarship (€766.67 plus social security contributions for each applicable month*) for the PhD student's stay abroad (if any), as authorised by the PhD Faculty pursuant to art. 9, paragraph 3 of Ministerial Decree dated no. 226 of 14 December 2021;

f) the sums required to cover any greater costs arising from the implementation of legislative and regulatory provisions.

Art. 3

1. IGI Terapeutics S.A. shall pay the amounts specified in art. 2 above to the University on the current account no. 000000463971 (ABI 03069; CAB 09400; CIN G; IBAN IT97 G030 6909 4000 0000 0463 971) in the name of Università degli Studi di Milano, c/o Intesa San Paolo S.p.A., Milan office, Via Verdi 8. The

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

amounts shall be paid in annual instalments, as follows:

- the first instalment of €45,000.00 shall be due by October 1st 2026.
- the second instalment of €30,000.00 shall be due by February 28 2027.

2. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico shall pay the amounts specified in art. 2 above to the University on the current account no. 000000463971 (ABI 03069; CAB 09400; CIN G; IBAN IT97 G030 6909 4000 0000 0463 971) in the name of Università degli Studi di Milano, c/o Intesa San Paolo S.p.A., Milan office, Via Verdi 8. The amounts shall be paid by February 28 2027.

The amounts under subparts e) and f) shall be paid to the University within 30 days of the written request from the latter.

Art. 4

Should the scholarship recipient withdraw from the programme, the sums paid out will be used, with the consent of both the Company and the Organization, to help cover programme costs or, after integrating the sum spent, to fund a new scholarship for the next PhD cycle.

Art. 5

The public competition for admission to the PhD programme, the organisation of the PhD programme, and the rights and obligations of PhD students shall be subject to the provisions set out in Ministerial Decree no. 226 dated 14 December 2021 "Regulations concerning the accreditation methods of doctoral locations and programmes and the criteria for the institution of doctoral programmes by accredited bodies" and in the University Regulations for PhD programmes and students, issued by Rector's Decree no. 0295540 of 5 June 2015, as subsequently

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

amended and supplemented.

Art. 6

It being understood that the training of the PhD student is the responsibility of the University, the tutor designated by the University shall be assisted by a co-tutor.

Art. 7

The University undertakes to maintain the confidentiality of research outcomes achieved during the PhD programme and not published in scientific journals, patented or published as a thesis, for the entire duration of the PhD programme.

Should research activities lead to new and innovative findings, which may or may not be patented, both the Company and/or the Organization shall notify the competent office of the University in a timely manner.

Pursuant to the provisions of the University Regulations on patents, the ownership, protection and use of such findings shall be governed by specific agreements between the parties.

Art. 8

The Company and the Organization undertake to host the PhD student at its headquarters and laboratories, for the purposes of carrying out the research project indicated in the recitals, subject to the authorisation of the Faculty of Instructors of the PhD programme.

Without prejudice to the University remaining the main place of activities, also for the purposes of travel reimbursements, the Company and the Organization co-funding the scholarship undertakes to make appropriate facilities available to the PhD student for his/her research activity, and to facilitate his/her professional

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

development to the best of its possibilities.

Should the scholarship recipient undertake with the consent of the Doctoral Board, research activities on the premises of the Company and/or the Organization, pursuant to article 2, paragraph 1, subpart a) of Legislative Decree 81/08 "Consolidated act on health and safety at work", the Company and/or the Organization undertake to comply with safety measures and obligations, as provided by the legislation in force. In particular:

a) the Company/Organization shall provide general and specific safety training in accordance with art. 37 of Legislative Decree 81/08, "Training of workers and their representatives";

b) the Company/Organization shall fulfil the obligations set out in articles 36 (Employee Information) and 41 (Health surveillance) of Legislative Decree 81/08, and provide Personal Protective Equipment (PPE) when required.

The scholarship recipient must respect disciplinary regulations as well as rules on hygiene, health and safety at work in force in the Company/Organization, and must preserve the confidentiality of data, information or knowledge of productive processes and products acquired during research activities.

Art. 9

The parties undertake to process personal data arising out of performance of this agreement, including those falling under the special categories of personal data, in accordance with Legislative Decree 196/2003 as subsequently amended and supplemented, and with Regulation (EU) 2016/679 (General Data Protection

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

Regulation). The Parties also declares that they will process personal data only for the purposes arising out of performance of this Agreement.

Art. 10

1. The Parties undertake to carry out all activities covered by this Agreement in full compliance with the fundamental values enshrined in the Constitution of the Italian Republic, the Statute and General Regulations of the University of Milan, and the Code of Ethics and for Research Integrity, with particular reference to the principles of freedom, human dignity, democracy, equality, solidarity, the promotion of peace, and respect for the environment.

2. All activities under this collaboration shall be conducted by the Parties in accordance with the principles of non-discrimination and equal treatment. The Parties undertake to refrain from any practice or activity that may constitute or promote direct or indirect discrimination based on personal characteristics protected by law.

3. The Parties are expressly prohibited from using the results of the research and cooperation activities covered by this Agreement for military purposes, for the production, development or support of instruments, technologies or activities connected with armed conflicts, or in any manner contrary to the principles of peace and respect for human rights.

4. Without prejudice to the provisions of paragraph 3, the Parties undertake to ensure that the subject matter of this Agreement does not involve the application, development or transfer of knowledge, technologies or methodologies referable to military or war-related purposes; the Parties further undertake to periodically

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

monitor their activities in order to verify compliance with the principles set forth in this Article and each Party shall have the right to promptly notify the other Party of any breach and to automatically terminate this Agreement, pursuant to Article 1456 of the Italian Civil Code, in the event of confirmed non-compliance with the obligations set forth in this Article.

Art. 11

This agreement is effective for three years (i.e. the duration of the PhD programme), starting from academic year 2026/2027.

Art. 12

The stamp duty shall be paid virtually pursuant to art. 7 of Ministerial Decree dated 23 January 2004, by the University.

In the event of its use, this agreement shall be registered pursuant to Presidential Decree no. 131 of 26 April 1986. Registration costs shall be borne by the Party interested.

DATE*

SIGNED BY**

The Rector of the University of Milan

(Marina Marzia Brambilla)

SIGNED BY**

DocuSigned by:
Dean Thomas
EEA09238BAD640C...

The General Counsel of IGI Therapeutics S.A.

(Dean Thomas)

Docusign Envelope ID: CBCF7763-FFAC-82EE-83A0-64AE9D81331F

SIGNED BY**

The Scientific Director of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

(Prof. Fabio Blandini)

*The date of execution corresponds to the date on which the last digital signature is affixed.

**Document signed with a digital signature in accordance with Legislative Decree No. 82 of 7 March 2005 and the Prime Ministerial Decree of 22 February 2013, as amended and supplemented.